Alinidine

Alinidine
Clinical data
ATC code none
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 33178-86-8 N
PubChem (CID) 36354
ChemSpider 33429 YesY
UNII E7IDJ8DS1D YesY
ChEMBL CHEMBL278581 YesY
Chemical and physical data
Formula C12H13Cl2N3
Molar mass 270.16 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Alinidine (ST567) is a negative chronotrope that was developed in the 1970s and 1980s. It causes bradycardia by inhibiting the pacemaker current by altering the maximal channel conductance and alter the voltage threshold.[1] The development of alinidine was halted because it was not sufficiently specific for its target. It also has a blocking effect on calcium channels and potassium channels. It also causes elongation of re-polarisation after an action potential.[2]

Alinidine did not improve outcomes among patients with acute myocardial infarction in a randomized controlled trial.[3]

References

  1. Snyders DJ, Van Bogaert P-P: Alinidine modifies the pacemaker current in sheep Purkinje fibers. Pflugers Arch 1987, 410:83-91
  2. Current Opinion in Pharmacology 2007, 7:208–213
  3. Van de Werf F, Janssens L, Brzostek T, Mortelmans L, Wackers FJ, Willems GM, et al. (1993). "Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy.". J Am Coll Cardiol. 22 (2): 407–16. doi:10.1016/0735-1097(93)90044-2. PMID 8335810.
This article is issued from Wikipedia - version of the 5/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.